Elsevier, a leading global publisher of scientific, technical, and medical information products and services, has announced that ClinicalPath has been selected as the "Best Computerized Decision Support Solution" in the 7th annual MedTech Breakthrough Awards program. This program recognizes the top companies, technologies, and products in the global health and medical technology market. This is ClinicalPath’s fourth year winning the award.
ClinicalPath, Elsevier’s evidence-based oncology clinical decision support tool, offers coverage of over 95% of the most common cancer cases in medical and radiation oncology. It helps cancer centers identify the right patients for their clinical trials and enables oncologists to make consistent, well-informed decisions for high-quality care. ClinicalPath’s oncology pathways provide the latest available clinical trials both within the organization and nationally.
Patient-specific clinical trials are surfaced based on detailed trial inclusion and exclusion criteria. This enables oncologists to identify eligible patients for screening and ultimately supports increased trial accrual. Supplemented by dynamic clinical trial analytics, ClinicalPath empowers healthcare leaders to open and close the right trials based on their patient population, identifies where gaps may exist in their current trial portfolio, and provides support to trial coordinators by eliminating some of the manual patient pre-screening efforts.
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work, and success in a range of health and medical technology categories. This year’s program attracted more than 4,000 nominations from over 17 different countries throughout the world.
Click here to read the original press release.
